Can a chemo pill snuff out hidden breast cancer cells?
NCT ID NCT07631052
First seen Jun 09, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This study tests whether the chemotherapy drug capecitabine can eliminate tiny amounts of cancer DNA still present in the blood after standard treatment for early-stage ER+/HER2- breast cancer. About 15 patients whose blood tests positive for this 'molecular residual disease' will take capecitabine pills for up to 12 months. The goal is to see if the drug can clear the cancer DNA and improve long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE I are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UHN - Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 1Z5, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Capecitabine (chemotherapy drug taken by mouth)
What this could lead to
If successful, this could offer a way to eliminate lingering cancer cells detected by a blood test, potentially reducing the risk of cancer returning.
What could go wrong
This is a very small early-phase trial (15 people) with no control group, so results may not apply broadly. Capecitabine can cause side effects like hand-foot syndrome and digestive issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.